Perseus Proteomics Inc. (TYO:4882)

Sage Therapeutics Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	1,667	1,541	2,444	3,214	1,069
Cash & Short-Term Investments	1,667	1,541	2,444	3,214	1,069
Cash Growth	8.18%	-36.95%	-23.96%	200.65%	121.78%
Accounts Receivable	22	13	9	10	8
Other Receivables	50	70	41	35	21
Receivables	72	83	50	45	29
Inventory	5	4	3	3	1
Prepaid Expenses	11	5	7	4	4
Other Current Assets	20	17	10	24	5
Total Current Assets	1,775	1,650	2,514	3,290	1,108
Long-Term Investments	42	42	51	9	9
Other Long-Term Assets	1	1	1	1	1
Total Assets	1,818	1,693	2,566	3,300	1,118
Accounts Payable	-	1	1	-	1
Accrued Expenses	41	57	28	11	8
Current Income Taxes Payable	79	66	66	134	24
Other Current Liabilities	4	4	16	3	1
Total Current Liabilities	124	128	111	148	34
Other Long-Term Liabilities	262	167	59	-	1
Total Liabilities	386	295	170	148	35
Common Stock	2,437	1,971	1,939	1,939	604
Additional Paid-In Capital	2,723	2,256	2,225	2,225	889
Retained Earnings	-3,808	-2,903	-1,799	-1,012	-413
Comprehensive Income & Other	80	74	31	-	3
Shareholders' Equity	1,432	1,398	2,396	3,152	1,083
Total Liabilities & Equity	1,818	1,693	2,566	3,300	1,118
Net Cash (Debt)	1,667	1,541	2,444	3,214	1,069
Net Cash Growth	8.18%	-36.95%	-23.96%	200.65%	121.78%
Net Cash Per Share	116.83	130.72	207.83	292.27	152.72
Filing Date Shares Outstanding	14.75	11.85	11.76	11.75	8.36
Total Common Shares Outstanding	14.75	11.85	11.76	11.75	8.36
Working Capital	1,651	1,522	2,403	3,142	1,074
Book Value Per Share	97.09	118.00	203.75	268.36	129.53
Tangible Book Value	1,432	1,398	2,396	3,152	1,083
Tangible Book Value Per Share	97.09	118.00	203.75	268.36	129.53

Source: S&P Global Market Intelligence. Standard template. Financial Sources.